CALR and neuroblastoma: Overall, the findings of this study demonstrate that treatment with angiotensin-converting enzyme inhibitors promotes the expression of calreticulin, low-density lipoprotein-receptor-related protein 1B, and 14-3-3 protein zeta/delta in neuroblastoma cells.